GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (ASX:ATX) » Definitions » PB Ratio

Amplia Therapeutics (ASX:ATX) PB Ratio : 1.87 (As of Dec. 15, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Amplia Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-15), Amplia Therapeutics's share price is A$0.086. Amplia Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was A$0.05. Hence, Amplia Therapeutics's PB Ratio of today is 1.87.

Warning Sign:

Amplia Therapeutics Ltd stock PB Ratio (=1.87) is close to 5-year high of 1.87

The historical rank and industry rank for Amplia Therapeutics's PB Ratio or its related term are showing as below:

ASX:ATX' s PB Ratio Range Over the Past 10 Years
Min: 0.18   Med: 0.71   Max: 57.05
Current: 1.87

During the past 11 years, Amplia Therapeutics's highest PB Ratio was 57.05. The lowest was 0.18. And the median was 0.71.

ASX:ATX's PB Ratio is ranked better than
61.2% of 1281 companies
in the Biotechnology industry
Industry Median: 2.48 vs ASX:ATX: 1.87

During the past 12 months, Amplia Therapeutics's average Book Value Per Share Growth Rate was -36.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -14.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -17.90% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -15.70% per year.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Amplia Therapeutics was 1.70% per year. The lowest was -27.90% per year. And the median was -15.55% per year.

Back to Basics: PB Ratio


Amplia Therapeutics PB Ratio Historical Data

The historical data trend for Amplia Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics PB Ratio Chart

Amplia Therapeutics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 2.72 1.29 1.04 1.31

Amplia Therapeutics Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.08 1.04 1.07 1.31 3.41

Competitive Comparison of Amplia Therapeutics's PB Ratio

For the Biotechnology subindustry, Amplia Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amplia Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's PB Ratio falls into.



Amplia Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Amplia Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=0.086/0.046
=1.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Amplia Therapeutics  (ASX:ATX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Amplia Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Amplia Therapeutics Business Description

Traded in Other Exchanges
Address
350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics Headlines

No Headlines